75.44

2.23% -1.72

Livanova Plc (LIVN)

Overview News Price History Option Chain Financials Discussions Forecast

Livanova Plc stock is traded at $75.44, with a volume of 1.05M. It is down -2.23% in the last 24 hours and down -3.60% over the past month. UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Previous Close:

$77.16

Open:

$77.26

24h Volume:

1.05M

Relative Volume:

1.57

Market Cap:

$4.16B

Revenue:

$1.43B

Net Income/Loss:

$107.13M

P/E Ratio:

38.94

EPS:

1.9372

Net Cash Flow:

$161.04M

1W Performance:

-3.02%

1M Performance:

-3.60%

6M Performance:

+20.90%

1Y Performance:

+41.72%

1-Day Range:

$74.11

$77.45

1-Week Range:

$74.11

$80.19

52-Week Range:

$48.82

$85.76

Livanova Plc Stock (LIVN) Company Profile

Name

Livanova Plc

Sector

Healthcare (1068)

Industry

Medical Devices (140)

Phone

4402033250662

Address

20 EASTBOURNE TERRACE, LONDON

Employee

3,300

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

LIVN's Discussions on Twitter

Compare LIVN vs ABT, MDT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LIVN Livanova Plc	75.44	4.16B	1.43B	107.13M	161.04M	1.9372
ABT Abbott Laboratories	101.07	174.89B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	88.51	113.22B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	269.75	103.47B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	44.68	64.75B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	85.73	49.41B	6.30B	1.07B	1.09B	1.8406

Livanova Plc Stock (LIVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-25	Initiated	KeyBanc Capital Markets	Overweight
Oct-01-25	Downgrade	Goldman	Buy → Neutral
May-20-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Feb-26-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-04-24	Initiated	Goldman	Buy
Sep-17-24	Upgrade	Robert W. Baird	Neutral → Outperform
Mar-20-24	Reiterated	Needham	Buy
Feb-20-24	Upgrade	Mizuho	Neutral → Buy
Sep-06-23	Initiated	HSBC Securities	Hold
Jul-19-23	Initiated	Robert W. Baird	Neutral
Apr-14-23	Initiated	Mizuho	Neutral
Dec-21-22	Initiated	Barclays	Equal Weight
Apr-06-22	Initiated	Wolfe Research	Outperform
Feb-24-22	Upgrade	UBS	Neutral → Buy
Dec-03-21	Initiated	Goldman	Buy
Aug-20-21	Reiterated	Needham	Buy
Jul-20-21	Upgrade	Needham	Hold → Buy
Mar-03-21	Downgrade	Berenberg	Buy → Hold
Jan-05-21	Downgrade	Needham	Buy → Hold
Sep-02-20	Initiated	Robert W. Baird	Outperform
Jun-26-20	Reiterated	Needham	Buy
Oct-30-19	Reiterated	Needham	Buy
Feb-28-19	Reiterated	Needham	Buy
Nov-28-18	Initiated	UBS	Neutral
Aug-02-18	Reiterated	Needham	Buy
Jun-08-18	Initiated	Stifel	Buy
May-31-18	Reiterated	Needham	Buy
Feb-28-18	Reiterated	Needham	Buy

View All

Livanova Plc Stock (LIVN) Latest News

Sep 24, 2026

Operating Leverage and Product Innovation Drive LivaNova’s(LIVN) Sustained Profit Outlook - Yahoo Finance

Sep 24, 2026